Scientists hunt for genetic clues to second breast cancer risk
NCT ID NCT00903591
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at why some women with breast cancer in one breast later develop cancer in the other breast. Researchers are comparing women with cancer in both breasts to those with cancer in only one breast. They are studying how genes, past radiation treatment, and lifestyle choices may increase the risk. The goal is to find better ways to detect, treat, and prevent breast cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
1,699 people
The number who actually took part.
- Started
-
May 2009
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
All of the WECARE:GWA Study participants (new cases and individually matched controls) will be identified, recruited, and interviewed by investigative teams in the five population-based cancer registries (NCC, OCR, FHCRC, Iowa, and DCS).
- Ages
-
18 to 54 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Eligibility for Cases: All women who meet the following eligibility requirements will be recruited as cases for the WECARE:GWA Study if they are not already cases (or refusers) from the parent WECARE Study: * Diagnosed since 1/1/1990 with a histologically confirmed first primary breast cancer (only invasive stage 1 or 2) while residing in one of the study enrollment site (cancer registry); * Diagnosed since 1/1/1992 with CBC (invasive only any stage) while residing in the same enrollment site (cancer registry); * Two years or longer time interval between first and second primaries; Between the ages of 18 and 54 at the time of diagnosis of the first primary; * Alive at time of contact; and * No history of previous or intervening cancer diagnosis, except cervical cancer in situ (CIS) or non-melanoma skin cancer. * Without bilateral mastectomy or prophylactic mastectomy of the contralateral breast following diagnosis of their first primary. Eligibility for Controls: Women who meet all of the following requirements will be eligible as controls. One matched control will be recruited for each participating case: * Diagnosed since 1/1/1990 with their first primary breast cancer (only invasive stage 1 or 2) while residing in one of the study enrollment site (i.e., cancer registry); * Between the ages of 18 and 54 at the time of diagnosis of the first primary; * Residing in the same study enrollment site (cancer registry) as when they were diagnosed with their breast cancer; * Alive at time of contact; * Never diagnosed (at reference date (date of first diagnosis plus "at risk interval" of matched case)) as having had CBC or any other cancer diagnosis other than the original breast cancer; with the exception of CIS or non-melanoma skin cancer. * Without bilateral mastectomy or prophylactic mastectomy of the contralateral breast following diagnosis of their first primary. Matching of Controls: Controls eligible for inclusion in this study will be individually matched (1:1) to cases on: * Enrollment site (cancer registry); * Age at diagnosis of the cases first primary(within 5-year age groups); * Year of diagnosis of the cases first primary;(within 4-year categories); * Race/ethnicity (white, black, Latina, Asian, other). Exclusion Criteria: Exclusion for Cases: Women with any of the following characteristics will be ineligible as a case: * Unable to speak English in U.S. or Canadian enrolling sites or Spanish in the California site, and Danish in Denmark * Unable to sign informed consent * Stage IV distant metastases for either the first or second primary (lymph node metastasis is acceptable, but there should be no organ involvement * Simultaneous diagnosis of invasive in one breast and in situ in the other breast Exclusion for Controls: Women with any of the following characteristics will be ineligible as a control: * Unable to speak English in U.S. and Canadian enrolling sites, or Spanish in the California site and Danish in Demark * Unable to sign informed consent * Stage IV distant metastases (lymph node metastasis is acceptable, but there should be no organ involvement
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bilateral breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Danish Cancer Society
Copenhagen, Denmark
-
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
ONTARIO CANCER REGISTRY, Mount Sinai Hospital, Toronto
Toronto, Ontario, M5G 1X5, Canada
-
Stanford University
Stanford, California, 94305, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?
- Tiny magnetic seeds could guide surgeons to the right lymph node
- New PET tracer aims to light up hidden cancer targets
- Gut bacteria supplement tested against chemo hair loss
- Can a mindfulness program boost Self-Compassion in breast cancer survivors?
- Can a Decades-Old Anti-Inflammatory drug quiet the joint pain that drives women off breast cancer therapy?